Loading...
•
Mar 31, 2022
Alkermes Q1 2022 Earnings Report
Alkermes reported strong financial results driven by LYBALVI®, ARISTADA®, and VIVITROL® sales and reiterated financial expectations for 2022.
Key Takeaways
Alkermes plc reported first quarter 2022 financial results, with total revenues of $278.5 million compared to $251.4 million for the same period in the prior year. The company reported a GAAP loss per share of $0.22 and non-GAAP earnings per share of $0.12. They reiterated their financial expectations for 2022.
Total revenues for the quarter were $278.5 million, compared to $251.4 million for the same period in the prior year.
Net sales of proprietary products for the quarter were $171.3 million, compared to $130.0 million for the same period in the prior year.
GAAP net loss was $35.9 million for the quarter, or a basic and diluted GAAP loss per share of $0.22.
Non-GAAP net income was $19.6 million for the quarter, or a non-GAAP basic and diluted earnings per share of $0.12.
Revenue by Segment
Forward Guidance
Alkermes reiterates its financial expectations for 2022, and the assumptions underlying such expectations, as set forth in its press release dated Feb. 16, 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...